EDX Medical Group told investors it has launched the Caris MI Clarity test in the UK, a prognostic tool the company describes as the first to assess both short and long-term risk of breast cancer recurrence in a single test.
The Cambridge-based diagnostics developer, which supplies molecular and digital tests focused on cancer and other diseases, said the test targets postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer, and gives a long-term risk read-out stretching up to 15 years.
EDX has struck an agreement with Caris Life Sciences, a US-based AI TechBio and precision medicine company, to supply the test in the UK.
The deal extends a relationship already in place between the two companies: EDX was appointed in July as Astron Health's UK supplier of Caris's MI Profile and Caris Assure platforms for tumour profiling.
Clinicians currently tend to assess early and late distant recurrence risk separately, which the companies say adds complexity to treatment planning.
Caris MI Clarity instead applies a multimodal AI model, combining imaging, clinical and molecular data, to stratify patients into low- or high-risk categories for both early recurrence (zero to five years) and late recurrence (five to 15 years) at the point of diagnosis.
Read more about EDX Medical
- 21/07/26EDX Medical launches bowel cancer test across UK
- 15/07/26EDX Medical signs three employers for £2m health screening rollout
- 08/07/26EDX Medical wins UK molecular profiling contract with global oncology firm Astron Health
"Bringing this truly pioneering test to the UK offers breast cancer patients and their doctors the opportunity to gain invaluable insight into the risk, both short and long term, of disease recurring", said Professor Sir Chris Evans, EDX's founder and chief scientific officer.
George W. Sledge, chief medical officer at Caris, said breast cancer clinicians have "long been forced to make some of the most consequential treatment decisions with an incomplete picture of how recurrence risk changes over time."
Chief executive Dr Mike Hudson said MI Clarity "fits superbly into our portfolio of advanced diagnostic tests."